This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Medical Services Advisory Committee. Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine. Canberra: Medical Services Advisory Committee (MSAC). MSAC application 1168. 2012

After considering the strength of the available evidence in relation to the safety, clinical effectiveness and cost-effectiveness of injecting botulinum toxin type A (Botox®) in refractory chronic migraine, MSAC supports its public funding via a new MBS item, with an MBS fee of $124.85 and an item descriptor, aligned with the PBS restriction, of: Botulinum toxin type A (Botox®), injection of, including all injections in one day, for the treatment of chronic migraine if: (a) the patient is an adult; and (b) the patient has experienced an inadequate response, intolerance or a contraindication to at least three prophylactic migraine medications prior to commencement of treatment with botulinum toxin as manifested by an average of 15 or more headache days per month, with at least 8 days of migraine, over a period of at least 6 months, prior to commencement of treatment with botulinum toxin; and (c) the requirements relating to botulinum toxin type A under the Pharmaceutical Benefits Scheme are complied with; and (d) treatment is only continued if the patient achieves and maintains a 50% or greater reduction from baseline in the number of headache days per month after two treatment cycles (each of 12 weeks duration).

Subject indexing assigned by CRD

Botulinum Toxins, Type As; Migraine Disorders

English

Australia

An English language summary is available.

MDP 106, GPO Box 9848, Canberra ACT 2601 AUSTRALIA Email: msac.secretariat@health.gov.au

32015000415

07/04/2015